ALLG members need a voice and a connection with Government bodies, the research and pharmaceutical sectors and each other. To facilitate this we have recently put considerable concentrated focus toward opportunities to create greater awareness of the ALLG and the members research efforts.

Our messaging and reach since January has included: a PBAC letter calling for action in the review of new medications that could improve the treatment of those with AML; four submissions to government addressing the National Research Infrastructure Capability Roadmap, the renewed NHMRC Safety Reporting framework, the revision of the NHMRC’s assessment for funding of clinical trials, and the proposal for Tax DGR Reform Opportunities to Treasury.

The ALLG submitted to the Senate Inquiry: Funding for Research into Cancers with Low Survival Rates, and received an invitation to address the Senate Committee on 7 June 2017. We would like to thank Professor's Mark Hertzberg and Andrew Roberts, and Peter Kempen Chairman for their wise and considered contributions to the Senators. We are hopeful this interaction will foster a closer relationship with government and help us achieve the much needed voice for the membership. The full transcript will be available in the coming months.

Title: Submitted To: Submission Date: Outcome:
National Research Infrastructure Capability Roadmap Joint call for comment by the Departments of Education & Training, Health, Industry Innovation & Science, and Environment & Energy. 16/01/2017 Expect final paper by September 2017.
Safety Consult — reporting and responsibilities NHMRC 30/03/2017 Pending final dissemination by NHMRC.
Senate Inquiry into Funding Low Survival Rate Cancers Australian Government Senate Inquiry 31/03/2017 Subsequent invitation to address Senate 7 June 2017. Findings report expected September 2017.
Funding Assessment for Clinical Trials NHMRC Clinical Trials 14/07/2017 Expect final position to be the adopted process for MRFF funding dispersed via NHMRC for clinical trials.
Tax DGR Reform Opportunities Treasury, Australian Government 13/07/2017 Final outcome expected October 2017.
AML Treatment (ALLG and HSANZ Joint) PBAC 17/07/2017 The PBAC reviewed the submission without delay, decision pending.